top

  Info

  • Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.

  Info

  • Utilizzare questo link per rimuovere la selezione effettuata.

Biblioteca

MARC Lista (tabellare)
Drug disposition and pharmacokinetics : principles and applications for medicine, toxicology and biotechnology / / Stephen H. Curry and Robin Whelpton
Drug disposition and pharmacokinetics : principles and applications for medicine, toxicology and biotechnology / / Stephen H. Curry and Robin Whelpton
Autore Curry Stephen H.
Edizione [Second edition.]
Pubbl/distr/stampa Hoboken, New Jersey : , : John Wiley & Sons, , [2022]
Descrizione fisica 1 online resource (480 pages)
Disciplina 615.7
Soggetto topico Pharmacokinetics
Biopharmaceutics
Drugs - Metabolism
ISBN 1-119-58918-5
1-119-58919-3
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Cover -- Title Page -- Copyright Page -- Contents -- Preface -- Chapter 1 Setting the Scene: Concepts, Nature of Drugs, and Quality of Results -- 1.1 Introduction -- 1.2 Concepts and terminology: disposition and pharmacokinetics -- 1.3 Pharmacokinetic parameters -- 1.3.1 Half-life -- 1.3.2 Clearance and apparent volume of distribution -- 1.3.3 Area under the plasma concentration-time curve -- 1.3.4 Apparent oral clearance -- 1.4 Time-concentration-effect relationships -- 1.5 Properties of drugs and xenobiotics -- 1.6 Quality of the data -- 1.6.1 Quantification of analyte concentrations -- 1.6.2 Timing of samples -- 1.6.3 Quality control and method validation -- 1.7 References -- Chapter 2 Drug Disposition and Fate -- 2.1 Introduction -- 2.2 Transport proteins -- 2.3 Absorption -- 2.3.1 Gastrointestinal tract -- 2.3.2 Drug transfer across the gastrointestinal tract -- 2.3.3 Other mucus membranes -- 2.3.4 Skeletal muscle -- 2.3.5 Skin -- 2.3.6 Absorption of macromolecules and nanoparticles -- 2.4 Distribution -- 2.4.1 Mechanisms of sequestration -- 2.4.2 Assessing the extent and location of distribution -- 2.4.3 Kinetics of distribution -- 2.5 Metabolism -- 2.5.1 Phase 1 metabolism -- 2.5.2 Phase 2 conjugations -- 2.5.3 Metabolism by microbiota -- 2.6 Excretion -- 2.6.1 Urine -- 2.6.2 Biliary excretion -- 2.6.3 Expired air -- 2.6.4 Saliva -- 2.6.5 Stomach and intestine -- 2.6.6 Breast milk -- 2.6.7 Other routes of excretion -- 2.6.8 Cycling processes -- 2.7 References -- Chapter 3 Pharmacokinetic Modelling -- 3.1 Introduction -- 3.2 Fundamental concepts -- 3.2.1 Apparent volume of distribution -- 3.2.2 Clearance -- 3.3 Elimination -- 3.3.1 First-order elimination -- 3.3.2 Non-linear elimination -- 3.4 Intravenous infusions -- 3.4.1 Single-compartment model with first-order elimination -- 3.4.2 Two-compartment model with first-order elimination.
3.5 First-order input and elimination -- 3.5.1 Absorption -- 3.5.2 Multiple dosing -- 3.6 Areas under the plasma concentration-time curve: trapezoidal method -- 3.7 Statistical moment theory -- 3.7.1 Estimating AUMC -- 3.8 Bioavailability and bioequivalence -- 3.8.1 Non-linear kinetics -- 3.8.2 Effect of systemic availability on plasma concentration-time curves -- 3.8.3 Factors affecting bioavailability -- 3.8.4 Bioequivalence -- 3.9 Physiological modelling -- 3.9.1 Practical considerations -- 3.10 Population kinetics -- 3.11 References -- Chapter 4 Pharmacokinetics of Metabolism and Excretion -- 4.1 Introduction -- 4.2 Metabolite kinetics -- 4.2.1 Basic concepts -- 4.2.2 Fraction of metabolite formed -- 4.2.3 More complex situations -- 4.2.4 Effect of pre-systemic metabolism -- 4.2.5 Interconversion of drug and metabolite -- 4.2.6 Active metabolites and prodrugs -- 4.2.7 Kinetics of formed and preformed metabolites -- 4.3 Kinetics of urinary excretion -- 4.3.1 Renal clearance -- 4.3.2 Effect of urine flow rate -- 4.3.3 Estimating renal blood flow and glomerular filtration rate -- 4.3.4 Specific drug examples -- 4.4 Excretion in faeces -- 4.5 References -- Chapter 5 Quantitative Pharmacological Relationships -- 5.1 Introduction -- 5.2 Concentration-effect relationships and dose-response curves -- 5.3 Concentration-effect relationships in vivo -- 5.4 Time-Dependent Models -- 5.4.1 Direct link and indirect link models -- 5.4.2 Temporal displacement -- 5.4.3 Inhomogeneity of plasma -- 5.4.4 Effects of unequal distribution in plasma -- 5.4.5 Pharmacokinetic distributional models -- 5.5 PK-PD modelling -- 5.5.1 PK-PD modelling under steady-state conditions -- 5.5.2 Use of effect-compartment models -- 5.5.3 Indirect-response models -- 5.5.4 Disease progression models -- 5.5.5 Time-related changes in pharmacodynamic parameters -- 5.5.6 Schedule dependence.
5.5.7 Basic PK-PD versus system PK-PD -- 5.6 References -- Chapter 6 Predictive Pharmacokinetics -- 6.1 Introduction -- 6.2 Physiochemical properties -- 6.2.1 Druggability -- 6.2.2 Drug-likeness -- 6.2.3 Dissolution studies -- 6.3 Metabolic stability -- 6.3.1 Microsomal intrinsic clearance -- 6.3.2 Hepatocytes -- 6.3.3 Recombinant human cytochromes -- 6.4 Plasma protein and tissue binding and blood/plasma ratios -- 6.4.1 Plasma protein binding -- 6.4.2 Erythrocyte concentrations -- 6.5 Hepatic clearance -- 6.5.1 Hepatic intrinsic clearance -- 6.5.2 Effect of plasma protein binding on elimination kinetics -- 6.6 Experimental methods of assessing transfer across biological membranes -- 6.6.1 Cell culture -- 6.6.2 Parallel artificial membrane permeability assay -- 6.6.3 Ussing chambers -- 6.6.4 Intestinal sacs -- 6.6.5 In vivo/in situ studies -- 6.7 Allometric scaling -- 6.7.1 Refinements to allometric scaling -- 6.7.2 Practical aspects of allometry -- 6.7.3 Method of Wajima -- 6.8 In silico predictions and PBPK modelling -- 6.9 Microdosing studies -- 6.10 Translational science -- 6.11 References -- Chapter 7 Disposition of Peptides and Other Biological Molecules -- 7.1 Introduction -- 7.2 Chemical aspects -- 7.2.1 PEGylation -- 7.3 Assay methods -- 7.4 Pharmacokinetics -- 7.4.1 Administration and dosage -- 7.4.2 Bioequivalence and biosimilarity -- 7.4.3 Distribution -- 7.4.4 Metabolism -- 7.4.5 Excretion -- 7.5 Plasma kinetics and pharmacodynamics -- 7.6 Examples of particular interest -- 7.6.1 Botulinum toxins -- 7.6.2 Cholecystokinins -- 7.6.3 Ciclosporin -- 7.6.4 Cocaine hydrolases -- 7.6.5 Erythropoietin -- 7.6.6 Heparin -- 7.6.7 Mipomersen -- 7.6.8 Somatotropin -- 7.6.9 Vasopressin and desmopressin -- 7.7 References -- Chapter 8 Monoclonal Antibodies -- 8.1 Introduction -- 8.2 Nomenclature -- 8.3 Circulation of monoclonal antibodies.
8.3.1 Convection -- 8.3.2 Neonatal Fc receptor -- 8.3.3 Binding to soluble target antigens -- 8.4 Pharmaceutical and DMPK aspects -- 8.4.1 Routes of administration -- 8.4.2 Distribution and apparent volume of distribution -- 8.4.3 Metabolism and excretion -- 8.4.4 Pharmacokinetics -- 8.4.5 Individual and population pharmacokinetics -- 8.5 Development of orally administered monoclonal antibodies -- 8.6 Optimizing pharmacokinetic and pharmacodynamic properties -- 8.7 Two highlighted early and durable examples -- 8.7.1 Trastuzumab -- 8.7.2 Adalimumab -- 8.8 PBPK modelling -- 8.9 Antibody-drug conjugates -- 8.9.1 Payloads -- 8.9.2 Linkers -- 8.9.3 Bystander killing -- 8.9.4 Disposition and pharmacokinetics -- 8.10 References -- Chapter 9 Drug Metabolism and Pharmacokinetics in Veterinary Sciences -- 9.1 Introduction -- 9.2 Areas of practice -- 9.2.1 Companion animal medicine -- 9.2.2 Treatment of animals of commerce -- 9.2.3 Zoos and wildlife preserves -- 9.2.4 Laboratory animal medicine -- 9.3 Scientific approach including allometric scaling -- 9.4 Information organized by pharmacokinetic processes -- 9.4.1 Administration -- 9.4.2 Absorption -- 9.4.3 Tissue distribution -- 9.4.4 Plasma protein binding and transporters -- 9.4.5 Metabolism -- 9.4.6 Excretion -- 9.5 Information organized by species and drugs -- 9.5.1 Mammals -- 9.5.2 Fish -- 9.6 Some drugs unique to veterinary science -- 9.7 Accidental exposure: toxicology - drugs used by humans that are dangerous to animals -- 9.7.1 Paracetamol in cats -- 9.7.2 Xanthines: chocolate in dogs -- 9.8 Residue analysis -- 9.9 References -- Chapter 10 Factors Affecting Plasma Concentrations: Consideration of Special Populations -- 10.1 Introduction -- 10.2 Pharmaceutical factors -- 10.3 Weight and obesity -- 10.3.1 Effects of obesity on pharmacokinetics -- 10.3.2 Dose adjustment in obesity.
10.3.3 Oral contraceptives -- 10.3.4 Gastric bypass surgery -- 10.3.5 Psychiatric patients -- 10.4 Food, diet, and nutrition -- 10.4.1 Diet and nutrition -- 10.5 Time of day -- 10.5.1 Circadian rhythms -- 10.5.2 Absorption -- 10.5.3 The liver -- 10.5.4 The kidneys -- 10.5.5 Intravenous and other injected doses -- 10.5.6 Pharmacodynamics -- 10.6 Posture and exercise -- 10.6.1 Exercise -- 10.7 Smoking -- 10.8 References -- Chapter 11 Pharmacogenetics, Pharmacogenomics, and Precision Medicine -- 11.1 Introduction -- 11.1.1 Terminology -- 11.2 Methods for the study of pharmacogenetics -- 11.2.1 Studies in twins -- 11.2.2 Phenotyping and genotyping -- 11.3 N-Acetyltransferase -- 11.3.1 Isoniazid -- 11.3.2 Sulfonamides -- 11.3.3 Other drugs -- 11.3.4 Genotyping N-acetyltransferase -- 11.4 Plasma cholinesterase -- 11.4.1 Suxamethonium -- 11.5 Carboxylesterases -- 11.6 Cytochrome P450 polymorphisms -- 11.6.1 Cytochrome 2D6 -- 11.6.2 Cytochrome 2C9 -- 11.6.3 Cytochrome 2C19 -- 11.6.4 Cytochromes 3A4/5 -- 11.6.5 Other cytochrome P450 polymorphisms -- 11.7 Glucose-6-phosphate dehydrogenase -- 11.7.1 Glucose-6-phosphate dehydrogenase deficiency -- 11.7.2 Triggering -- 11.7.3 Effects on pharmacokinetics -- 11.8 Alcohol dehydrogenase and acetaldehyde dehydrogenase -- 11.9 Thiopurine methyltransferase -- 11.10 Phase 2 enzymes -- 11.10.1 UDP-glucuronosyltransferases -- 11.10.2 Sulfotransferases -- 11.10.3 Glutathione transferases -- 11.11 Transporters -- 11.12 Pharmacodynamic differences -- 11.13 Ethnicity -- 11.14 Personalized medicine -- 11.15 References -- Chapter 12 Effects of Sex and Pregnancy on Drug Disposition and Pharmacokinetics -- 12.1 Introduction -- 12.1.1 Studies in animals -- 12.2 Effect of sex on human drug disposition and pharmacokinetics -- 12.2.1 Absorption and bioavailability -- 12.2.2 Distribution -- 12.2.3 Metabolism -- 12.2.4 Excretion.
12.2.5 Effects.
Record Nr. UNINA-9910677278003321
Curry Stephen H.  
Hoboken, New Jersey : , : John Wiley & Sons, , [2022]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Drug disposition and pharmacokinetics : from principles to applications / / Stephen H. Curry, Robin Whelpton
Drug disposition and pharmacokinetics : from principles to applications / / Stephen H. Curry, Robin Whelpton
Autore Curry Stephen H.
Edizione [2nd ed.]
Pubbl/distr/stampa Chichester, West Sussex, England : , : Wiley-Blackwell, , 2011
Descrizione fisica 1 online resource (840 p.)
Disciplina 615.7
615/.7
Soggetto topico Pharmacokinetics
Biopharmaceutics
Drugs - Metabolism
Soggetto genere / forma Electronic books.
ISBN 0-470-66522-X
0-470-66519-X
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Cover; Title; Copyright; Preface; About the Authors; 1: Chemical Introduction: Sources, Classification and Chemical Properties of Drugs; 1.1 Introduction; 1.2 Drug nomenclature and classification; 1.3 Properties of molecules; 1.4 Physicochemical interactions between drugs and other chemicals; 1.5 Law of mass action; 1.6 Ionization; 1.7 Partition coefficients; 1.8 Stereochemistry; Further reading and references; 2: Drug Administration and Distribution; 2.1 Introduction; 2.2 Drug transfer across biological membranes; 2.3 Drug administration; 2.4 Drug distribution; 2.5 Plasma protein binding
2.6 SummaryReferences and further reading; 3: Drug Elimination; 3.1 Introduction; 3.2 Metabolism; 3.3 Excretion; References and further reading; 4: Elementary Pharmacokinetics; 4.1 Introduction; 4.2 Single-compartment models; 4.3 Non-linear kinetics; 4.4 Relationship between dose, onset and duration of effect; 4.5 Limitations of single-compartment models; 4.6 Summary; References and further reading; 5: More Complex and Model Independent Pharmacokinetic Models; 5.1 Introduction; 5.2 Multiple compartment models; 5.3 Curve fitting and choice of most appropriate model
5.4 Model independent approaches5.5 Population pharmacokinetics; 5.6 Summary; References and further reading; 6: Kinetics of Metabolism and Excretion; 6.1 Introduction; 6.2 Metabolite kinetics; 6.3 Renal excretion; 6.4 Excretion in faeces; References and further reading; 7: Further Consideration of Clearance, and Physiological Modelling; 7.1 Introduction; 7.2 Clearance in vitro (metabolic stability); 7.3 Clearance in vivo; 7.4 Hepatic intrinsic clearance; 7.5 In vitro to in vivo extrapolation; 7.6 Limiting values of clearance; 7.7 Safe and effective use of clearance
7.8 Physiological modelling7.9 Inhomogeneity of plasma; References and further reading; 8: Drug Formulation: Bioavailability, Bioequivalence and Controlled-Release Preparations; 8.1 Introduction; 8.2 Dissolution; 8.3 Systemic availability; 8.4 Formulation factors affecting bioavailability; 8.5 Bioequivalence; 8.6 Controlled-release preparations; 8.7 Conclusions; References and further reading; 9: Factors Affecting Plasma Concentrations; 9.1 Introduction; 9.2 Time of administration of dose; 9.3 Food, diet and nutrition; 9.4 Smoking; 9.5 Circadian rhythms; 9.6 Weight and obesity; 9.7 Sex
9.8 Pregnancy9.9 Ambulation, posture and exercise; References and further reading; 10: Pharmacogenetics and Pharmacogenomics; 10.1 Introduction; 10.2 Methods for the study of pharmacogenetics; 10.3 N-acetyltransferase; 10.4 Plasma cholinesterase; 10.5 Cytochrome P450 polymorphisms; 10.6 Alcohol dehydrogenase and acetaldehyde dehydrogenase; 10.7 Thiopurine methyltransferase; 10.8 Phase 2 enzymes; 10.9 Transporters; 10.10 Pharmacodynamic differences; References and further reading; 11: Developmental Pharmacology and Age-related Phenomena; 11.1 Introduction
11.2 Scientific and regulatory environment in regard to younger and older patients
Record Nr. UNINA-9910139399403321
Curry Stephen H.  
Chichester, West Sussex, England : , : Wiley-Blackwell, , 2011
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Drug disposition and pharmacokinetics : from principles to applications / / Stephen H. Curry, Robin Whelpton
Drug disposition and pharmacokinetics : from principles to applications / / Stephen H. Curry, Robin Whelpton
Autore Curry Stephen H.
Edizione [2nd ed.]
Pubbl/distr/stampa Chichester, England : , : Wiley-Blackwell, , [2011]
Descrizione fisica 1 online resource (840 p.)
Disciplina 615.7
Soggetto topico Biopharmaceutics
Drugs - Metabolism
ISBN 0-470-66522-X
0-470-66519-X
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Cover; Title; Copyright; Preface; About the Authors; 1: Chemical Introduction: Sources, Classification and Chemical Properties of Drugs; 1.1 Introduction; 1.2 Drug nomenclature and classification; 1.3 Properties of molecules; 1.4 Physicochemical interactions between drugs and other chemicals; 1.5 Law of mass action; 1.6 Ionization; 1.7 Partition coefficients; 1.8 Stereochemistry; Further reading and references; 2: Drug Administration and Distribution; 2.1 Introduction; 2.2 Drug transfer across biological membranes; 2.3 Drug administration; 2.4 Drug distribution; 2.5 Plasma protein binding
2.6 SummaryReferences and further reading; 3: Drug Elimination; 3.1 Introduction; 3.2 Metabolism; 3.3 Excretion; References and further reading; 4: Elementary Pharmacokinetics; 4.1 Introduction; 4.2 Single-compartment models; 4.3 Non-linear kinetics; 4.4 Relationship between dose, onset and duration of effect; 4.5 Limitations of single-compartment models; 4.6 Summary; References and further reading; 5: More Complex and Model Independent Pharmacokinetic Models; 5.1 Introduction; 5.2 Multiple compartment models; 5.3 Curve fitting and choice of most appropriate model
5.4 Model independent approaches5.5 Population pharmacokinetics; 5.6 Summary; References and further reading; 6: Kinetics of Metabolism and Excretion; 6.1 Introduction; 6.2 Metabolite kinetics; 6.3 Renal excretion; 6.4 Excretion in faeces; References and further reading; 7: Further Consideration of Clearance, and Physiological Modelling; 7.1 Introduction; 7.2 Clearance in vitro (metabolic stability); 7.3 Clearance in vivo; 7.4 Hepatic intrinsic clearance; 7.5 In vitro to in vivo extrapolation; 7.6 Limiting values of clearance; 7.7 Safe and effective use of clearance
7.8 Physiological modelling7.9 Inhomogeneity of plasma; References and further reading; 8: Drug Formulation: Bioavailability, Bioequivalence and Controlled-Release Preparations; 8.1 Introduction; 8.2 Dissolution; 8.3 Systemic availability; 8.4 Formulation factors affecting bioavailability; 8.5 Bioequivalence; 8.6 Controlled-release preparations; 8.7 Conclusions; References and further reading; 9: Factors Affecting Plasma Concentrations; 9.1 Introduction; 9.2 Time of administration of dose; 9.3 Food, diet and nutrition; 9.4 Smoking; 9.5 Circadian rhythms; 9.6 Weight and obesity; 9.7 Sex
9.8 Pregnancy9.9 Ambulation, posture and exercise; References and further reading; 10: Pharmacogenetics and Pharmacogenomics; 10.1 Introduction; 10.2 Methods for the study of pharmacogenetics; 10.3 N-acetyltransferase; 10.4 Plasma cholinesterase; 10.5 Cytochrome P450 polymorphisms; 10.6 Alcohol dehydrogenase and acetaldehyde dehydrogenase; 10.7 Thiopurine methyltransferase; 10.8 Phase 2 enzymes; 10.9 Transporters; 10.10 Pharmacodynamic differences; References and further reading; 11: Developmental Pharmacology and Age-related Phenomena; 11.1 Introduction
11.2 Scientific and regulatory environment in regard to younger and older patients
Record Nr. UNINA-9910830057203321
Curry Stephen H.  
Chichester, England : , : Wiley-Blackwell, , [2011]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Emerging non-clinical biostatistics in biopharmaceutical development and manufacturing / / Harry Yang, MedImmune, LLC, Gaithersburg, Maryland, USA
Emerging non-clinical biostatistics in biopharmaceutical development and manufacturing / / Harry Yang, MedImmune, LLC, Gaithersburg, Maryland, USA
Autore Yang Harry
Pubbl/distr/stampa Boca Raton, Florida : , : CRC Press, , [2017]
Descrizione fisica 1 online resource (387 pages) : illustrations
Disciplina 615.19
Collana Chapman & Hall/CRC Biostatistics Series
Soggetto topico Biometry
Biopharmaceutics
ISBN 1-315-35445-4
1-315-37172-3
1-4987-0416-6
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto section 1. Background -- section 2. Analytical method -- section 3. Process development -- section 4. Manufacturing.
Record Nr. UNINA-9910154882703321
Yang Harry  
Boca Raton, Florida : , : CRC Press, , [2017]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
European journal of pharmaceutics and biopharmaceutics
European journal of pharmaceutics and biopharmaceutics
Pubbl/distr/stampa [New York, NY], : Elsevier Science
Soggetto topico Biopharmaceutics
Drugs
Pharmaceutical technology
Pharmaceutical technology - Periodicals
Biopharmaceutics - Periodicals
Technology, Pharmaceutical
Techniques pharmaceutiques - Périodiques
Médicaments
Biopharmacie - Périodiques
Biopharmacie
Techniques pharmaceutiques
Soggetto genere / forma Periodicals.
ISSN 1873-3441
Formato Materiale a stampa
Livello bibliografico Periodico
Lingua di pubblicazione eng
Altri titoli varianti EJPB
Record Nr. UNISA-996204933003316
[New York, NY], : Elsevier Science
Materiale a stampa
Lo trovi qui: Univ. di Salerno
Opac: Controlla la disponibilità qui
European journal of pharmaceutics and biopharmaceutics
European journal of pharmaceutics and biopharmaceutics
Pubbl/distr/stampa [New York, NY], : Elsevier Science
Soggetto topico Biopharmaceutics
Drugs
Pharmaceutical technology
Pharmaceutical technology - Periodicals
Biopharmaceutics - Periodicals
Technology, Pharmaceutical
Techniques pharmaceutiques - Périodiques
Médicaments
Biopharmacie - Périodiques
Biopharmacie
Techniques pharmaceutiques
Soggetto genere / forma Periodicals.
ISSN 1873-3441
Formato Materiale a stampa
Livello bibliografico Periodico
Lingua di pubblicazione eng
Altri titoli varianti EJPB
Record Nr. UNINA-9910147039203321
[New York, NY], : Elsevier Science
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Formulation and process development strategies for manufacturing biopharmaceuticals [[electronic resource] /] / edited by Feroz Jameel, Susan Hershenson
Formulation and process development strategies for manufacturing biopharmaceuticals [[electronic resource] /] / edited by Feroz Jameel, Susan Hershenson
Pubbl/distr/stampa Hoboken, N.J., : Wiley, c2010
Descrizione fisica 1 online resource (986 p.)
Disciplina 615.19
615/.7
Altri autori (Persone) JameelFeroz
HershensonSusan
Soggetto topico Biopharmaceutics
Pharmaceutical technology
ISBN 1-282-70758-2
9786612707582
0-470-59588-4
0-470-59587-6
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto FORMULATION AND PROCESS DEVELOPMENT STRATEGIES FOR MANUFACTURING BIOPHARMACEUTICALS; CONTENTS; FOREWORD; PREFACE; CONTRIBUTORS; PART I PREFORMULATION AND DEVELOPMENT OF STABILITY-INDICATING ASSAYS: BIOPHYSICAL CHARACTERIZATION TECHNIQUES; 1 THE STRUCTURE OF BIOLOGICAL THERAPEUTICS; 2 CHEMICAL INSTABILITY IN PEPTIDE AND PROTEIN PHARMACEUTICALS; 3 PHYSICAL STABILITY OF PROTEIN PHARMACEUTICALS; 4 IMMUNOGENICITY OF THERAPEUTIC PROTEINS; 5 PREFORMULATION RESEARCH: ASSESSING PROTEIN; 6 FORMULATION DEVELOPMENT OF PHASE 1-2 BIOPHARMACEUTICALS: AN EFFICIENT AND TIMELY APPROACH
7 LATE-STAGE FORMULATION DEVELOPMENT AND CHARACTERIZATION OF BIOPHARMACEUTICALS8 AN EMPIRICAL PHASE DIAGRAM-HIGH-THROUGHPUT SCREENING APPROACH TO THE CHARACTERIZATION AND FORMULATION OF BIOPHARMACEUTICALS; 9 FLUORESCENCE AND PHOSPHORESCENCE METHODS TO PROBE PROTEIN STRUCTURE AND STABILITY IN ICE: THE CASE OF AZURIN; 10 APPLICATIONS OF SEDIMENTATION VELOCITY ANALYTICAL ULTRACENTRIFUGATION; 11 FIELD FLOW FRACTIONATION WITH MULTIANGLE LIGHT SCATTERING FOR MEASURING PARTICLE SIZE DISTRIBUTIONS OF VIRUS-LIKE PARTICLES
12 LIGHT-SCATTERING TECHNIQUES AND THEIR APPLICATION TO FORMULATION AND AGGREGATION CONCERNSPART II DEVELOPMENT OF A FORMULATION FOR LIQUID DOSAGE FORM; 13 EFFECTIVE APPROACHES TO FORMULATION DEVELOPMENT OF BIOPHARMACEUTICALS; 14 PREDICTION OF AGGREGATION PROPENSITY FROM PRIMARY SEQUENCE INFORMATION; 15 HIGH-CONCENTRATION ANTIBODY FORMULATIONS; 16 DEVELOPMENT OF FORMULATIONS FOR THERAPEUTIC MONOCLONAL ANTIBODIES AND Fc FUSION PROTEINS; 17 REVERSIBLE SELF-ASSOCIATION OF PHARMACEUTICAL PROTEINS: CHARACTERIZATION AND CASE STUDIES; PART III DEVELOPMENT OF A FORMULATION FOR LYOPHILIZED DOSAGE FORM
18 DESIGN OF A FORMULATION FOR FREEZE DRYING19 PROTEIN CONFORMATION AND REACTIVITY IN AMORPHOUS SOLIDS; 20 THE IMPACT OF BUFFER ON SOLID-STATE PROPERTIES AND STABILITY OF FREEZE-DRIED DOSAGE FORMS; 21 STABILIZATION OF LYOPHILIZED PHARMACEUTICALS BY CONTROL OF MOLECULAR MOBILITY: IMPACT OF THERMAL HISTORY; 22 STRUCTURAL ANALYSIS OF PROTEINS IN DRIED MATRICES; 23 THE IMPACT OF FORMULATION AND DRYING PROCESSES ON THE CHARACTERISTICS AND PERFORMANCE OF BIOPHARMACEUTICAL POWDERS; PART IV MANUFACTURING SCIENCES; 24 MANUFACTURING FUNDAMENTALS FOR BIOPHARMACEUTICALS
25 PROTEIN STABILITY DURING BIOPROCESSING26 FREEZING AND THAWING OF PROTEIN SOLUTIONS; 27 STRATEGIES FOR BULK STORAGE AND SHIPMENT OF PROTEINS; 28 DRYING PROCESS METHODS FOR BIOPHARMACEUTICAL PRODUCTS: AN OVERVIEW; 29 SPRAY DRYING OF BIOPHARMACEUTICALS AND VACCINES; 30 DEVELOPMENT AND OPTIMIZATION OF THE FREEZE-DRYING PROCESSES; 31 CONSIDERATIONS FOR SUCCESSFUL LYOPHILIZATION PROCESS SCALE-UP, TECHNOLOGY TRANSFER, AND ROUTINE PRODUCTION; 32 PROCESS ROBUSTNESS IN FREEZE DRYING OF BIOPHARMACEUTICALS; 33 FILLING PROCESSES AND TECHNOLOGIES FOR LIQUID BIOPHARMACEUTICALS
34 LEACHABLES AND EXTRACTABLES
Record Nr. UNINA-9910140773403321
Hoboken, N.J., : Wiley, c2010
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Freeze-drying of pharmaceuticals and biopharmaceuticals [[electronic resource] ] : [principles and practice] / / Felix Franks ; in association with Tony Auffret
Freeze-drying of pharmaceuticals and biopharmaceuticals [[electronic resource] ] : [principles and practice] / / Felix Franks ; in association with Tony Auffret
Autore Franks Felix
Pubbl/distr/stampa Cambridge, : RSC Publishing, c2007
Descrizione fisica 1 online resource (219 p.)
Disciplina 615.18
Altri autori (Persone) AuffretTony
Soggetto topico Frozen drugs
Freeze-drying
Biopharmaceutics
Soggetto genere / forma Electronic books.
ISBN 1-84755-770-8
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Freeze-drying of Pharmaceuticals and Biopharmaceuticals_publicity; i_iv; v_viii; ix_xii; 001_012; 013_019; 020_027; 028_053; 054_077; 078_088; 089_104; 105_120; 121_129; 130_140; 141_170; 171_181; 182_186; 187_189; 190_200; 201_206
Record Nr. UNINA-9910462209703321
Franks Felix  
Cambridge, : RSC Publishing, c2007
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Freeze-drying of pharmaceuticals and biopharmaceuticals : [principles and practice] / / Felix Franks ; in association with Tony Auffret
Freeze-drying of pharmaceuticals and biopharmaceuticals : [principles and practice] / / Felix Franks ; in association with Tony Auffret
Autore Franks Felix
Pubbl/distr/stampa Cambridge : , : RSC Publishing, , 2007
Descrizione fisica 1 online resource (xii, 206 pages) : illustrations
Disciplina 615.18
Altri autori (Persone) AuffretTony
Soggetto topico Frozen drugs
Freeze-drying
Biopharmaceutics
ISBN 1-84755-770-8
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910786355203321
Franks Felix  
Cambridge : , : RSC Publishing, , 2007
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Freeze-drying of pharmaceuticals and biopharmaceuticals : [principles and practice] / / Felix Franks ; in association with Tony Auffret
Freeze-drying of pharmaceuticals and biopharmaceuticals : [principles and practice] / / Felix Franks ; in association with Tony Auffret
Autore Franks Felix
Pubbl/distr/stampa Cambridge : , : RSC Publishing, , 2007
Descrizione fisica 1 online resource (xii, 206 pages) : illustrations
Disciplina 615.18
Altri autori (Persone) AuffretTony
Soggetto topico Frozen drugs
Freeze-drying
Biopharmaceutics
ISBN 1-84755-770-8
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910813400103321
Franks Felix  
Cambridge : , : RSC Publishing, , 2007
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui